Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.

@article{Isakova2015RationaleAA,
  title={Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.},
  author={Tamara Isakova and Joachim H. Ix and Stuart M. Sprague and Kalani L Raphael and Linda F. Fried and Jennifer J. Gassman and Dominic S. C. Raj and Alfred K. Cheung and John W. Kusek and Michael Francis Flessner and Myles Wolf and Geoffrey A. Block},
  journal={Journal of the American Society of Nephrology : JASN},
  year={2015},
  volume={26 10},
  pages={
          2328-39
        }
}
Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet available therapies only modestly improve clinical outcomes. Observational studies report independent associations between elevated serum phosphate and fibroblast growth factor 23 (FGF23) levels and risks of ESRD, CVD, and death. Phosphate excess induces arterial calcification, and although elevated FGF23 helps maintain serum phosphate levels in the normal range in CKD, it may contribute mechanistically to… Expand
Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study
TLDR
The primary objective of the IMPROVE-CKD study is to determine if the use of lanthanum carbonate reduces the burden of cardiovascular disease in patients with CKD stages 3b and 4 when compared with placebo. Expand
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
TLDR
In patients with stage 3b/4 CKD, treatment with lanthanum over 96 weeks did not affect arterial stiffness or aortic calcification compared with placebo, and the role of intestinal phosphate binders to reduce cardiovascular risk in patients with CKD who have normophosphatemia is not supported. Expand
Should phosphate management be limited to the KDIGO/ KDOQI guidelines?
TLDR
There has been a lack of high quality evidence demonstrating beneficial effects of phosphate lowering therapy on clinical outcomes, and there is no definitive data as to whether effective phosphate control with phosphate binders will prevent elevations in FGF 23, and whether lowering FGF23 levels will lead to improved patient outcomes. Expand
Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho.
TLDR
Mounting evidence supports a well-supported protective role for α-Klotho on VC and a thorough systemic evaluation of the biomedical interplay of phosphate, FGF23, and α-Lotho may potentially lead to new therapeutic options for patients with CKD-MBD. Expand
Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony
TLDR
It is suggested that FGF23 are elevated and may also be a risk factor for cardiovascular disease and mortality in type 2 diabetes patients without CKD, although the magnitude of the association is smaller than in CKD patients. Expand
Total Phosphate Elimination is Negatively Associated With Increased Serum Fibroblast Growth Factor 23 Levels in Patients who Undergo Peritoneal Dialysis
  • S. Yamada, K. Tsuruya, +4 authors T. Kitazono
  • Medicine
  • Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • 2017
TLDR
It is indicated that maintaining phosphate elimination can prevent increased sFGF23, thereby preventing cardiovascular events in patients who undergo PD. Expand
Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
Iron deficiency, anemia, hyperphosphatemia, and increased fibroblast growth factor 23 (FGF23) are common and interrelated complications of chronic kidney disease (CKD) that are linked to CKDExpand
The role of calcium and non calcium‐based phosphate binders in chronic kidney disease
TLDR
In general, it seems prudent to avoid prescribing calcium‐based drugs to patients who are pre‐dialysis, and to use non‐CBBs preferentially in CKD stage 5D, while current draft Kidney Disease Improving Global Outcomes guidelines suggest that CBB dosage be minimized in CKd stages 3 to 5D. Expand
The Urinary Phosphate to Serum Fibroblast Growth Factor 23 Ratio Is a Useful Marker of Atherosclerosis in Early-Stage Chronic Kidney Disease
TLDR
It is suggested that a decrease in nephron index reflects early-stage renal impairment and is an independent risk factor of macroangiopathy in diabetic patients. Expand
Extrarenal effects of FGF23
TLDR
The results of recent experimental studies indicate that FGF23 directly impacts on hippocampal neurons and may thereby impair learning and memory function in CKD patients, and it has been shown that F GF23 interferes with the immune system by directly acting on polymorphonuclear leukocytes and macrophages. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 140 REFERENCES
Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease
TLDR
It is suggested that future population-level and individual-level interventions will need to simultaneously target these molecules to reduce the risk of associated cardiovascular events. Expand
Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?
TLDR
Prospective and long-term studies are necessary to confirm the effects of sevelamer on serum FGF23 and the benefits of this decrease on outcomes and the positive effects of early prescription of phosphate binders on PTH control. Expand
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
TLDR
Increased FGF23 is a common manifestation of CKD that develops earlier than increased phosphate or PTH, and may be a sensitive early biomarker of disordered phosphorus metabolism in patients with CKD and normal serum phosphate levels. Expand
Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.
  • T. Isakova, O. Gutiérrez, +4 authors M. Wolf
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2011
TLDR
Although dietary phosphorus restriction and lanthanum lowered urinary phosphate excretion consistent with a rapid decrease in phosphorus absorption, inducing a reduction in FGF23 levels in CKD patients may require interventions with a longer duration than in healthy volunteers. Expand
Effects of Phosphate Binder Therapy on Vascular Stiffness in Early-Stage Chronic Kidney Disease
TLDR
Twelve months of LaCO3 had no effect on serum phosphorus and did not alter phosphate homeostasis, PWV, cIMT, VC, or biomarkers of CKD-MBD. Expand
Forging forward with 10 burning questions on FGF23 in kidney disease.
  • M. Wolf
  • Medicine
  • Journal of the American Society of Nephrology : JASN
  • 2010
TLDR
A proliferation of studies linking phosphorus and now FGF23 excess to adverse renal and cardiovascular outcomes in patients with CKD is setting the stage for novel clinical trials that could ultimately bring FGF 23 testing into the clinic. Expand
Mineral metabolites and CKD progression in African Americans.
TLDR
In conclusion, abnormalities of mineral metabolism worsen with progressive CKD and associate with higher risk for ESRD among African Americans with hypertensive nephrosclerosis. Expand
Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.
TLDR
The combination of LC plus counseling for a phosphate-restricted diet decreased FGF23 levels in patients with CKD stages 3-4 and normal serum phosphate levels. Expand
Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease.
TLDR
FGF23 normalizes serum phosphate and decreases 1, 25-dihydroxyvitamin D levels in early-stage CKD, and suggests a pathological sequence of events for the development of secondary hyperparathyroidism triggered by increased FGF23, followed by a reduction of 1,25-dhydroxy vitamin D and calcium levels, thereby increasing parathyroid hormone secretion. Expand
Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.
  • M. Yılmaz, A. Sonmez, +9 authors C. Zoccali
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2012
TLDR
In hyperphosphatemic patients with stage 4 CKD, treatment with phosphate lowering induces measurable improvements in flow-mediated vasodilatation, compatible with the hypothesis that FGF-23 may contribute to vascular dysfunction in this population. Expand
...
1
2
3
4
5
...